Healthy
Conditions
Brief summary
The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy participants. Participation could last up to 7 weeks
Interventions
DRUGLY4100511
Administered orally
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants must be able to understand and comply with the requirements of the study, as judged by the Investigator. * Participants must have a body mass index (BMI) ≥ 18 and ≤ 35 kilograms per meter squared (kg/m2).
Exclusion criteria
* History or presence of any clinically relevant acute or chronic medical or psychiatric condition that could interfere with the participant's safety during the clinical study or expose the participant to undue risk as judged by the Investigator. * Malignancy within the past 5 years of screening with the exception of in situ removal of basal cell carcinoma, resected benign colonic polyps, or adequately treated cervix carcinoma in-situ. * Planned major surgery within duration of the study or the 30 days following study completion. * Females who are pregnant, breast feeding, lactating or plan to be pregnant during the study period or 90 days after. * History of any drug and/or alcohol abuse in the past 2 years prior to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Part 1 | Baseline up to 6 Days |
| Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Part 2 | Baseline up to 7 Days |
Countries
United Kingdom
Outcome results
None listed